Narayana Hrudaya Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,475Cr
- +18.4% YoY
- +10.5% QoQ
- Net profit
- ₹197Cr
- +3.1% YoY
- +2.1% QoQ
- Margin
- 24%
- +1 pp YoY
- +1 pp QoQ
Guidance rank: #27 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
The company aspires to improve profitability every year.
From Narayana Hrudaya's Q4 FY25 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Expansion plans include new facilities in Kolkata, Raipur, Shimoga, and exploration of other markets with strong presence for organic growth.
- Oncology and orthopedics are growing roughly at 20-25%; cardiac business expected to maintain 25-30% growth over three years.
- India business projected to grow ~14-15% standalone, excluding international patient flows.
- International patient revenue has bottomed out and expected to decline to zero, impacting margins positively due to higher domestic realization.
2 more points from Narayana Hrudaya's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Narayana Hrudaya said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY26 capex guidance is around INR 400-450 crores excluding replacement costs; INR 425 crores projected spend (Page 15).
- Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based on construction progress (Page 12 & 15).
- Capex amounts are based on committed projects; delays or opportunities may push spends to FY27/FY28 (Page 15).
- Debt will fund about 60-65% of total capex, with remaining funded from internal resources (Page 16 & 13).
- Large cash corpus (~INR 1,600 crores) can be used for new projects or repayment of high-interest loans (Page 16).
2 more points from Narayana Hrudaya's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Narayana Hrudaya said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Narayana Hrudaya said on order book & pipeline — free account, 30 seconds.
Narayana Hrudaya — Quarterly revenue & net profit
Narayana Hrudaya Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,475 | 1,246 | +18.4% | 1,335 | +10.5% |
| Operating profit (EBITDA) | 358 | 291 | +23% | 307 | +16.6% |
| Operating margin | 24% | 23% | +1 pp | 23% | +1 pp |
| Profit before tax | 254 | 225 | +12.9% | 219 | +16% |
| Net profit (PAT) | 197 | 191 | +3.1% | 193 | +2.1% |
| EPS (₹) | 9.65 | 9.33 | +3.4% | 9.44 | +2.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.8K Cr, net profit ₹301 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Narayana Hrudaya's management said in earlier quarters
Others in Healthcare Services this season
- 3B Blackbio (Q4 FY25)
UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…
- Apollo Hospitals (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
- Healthcare Global Enterprises (Q4 FY25)
FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores. Key concall takeaways from Healthcare Global Enterprises Ltd's Q4 FY25…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Narayana Hrudaya and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Narayana Hrudaya Q4 FY25 results?
The company aspires to improve profitability every year.
What is Narayana Hrudaya share price analysis?
Narayana Hrudaya currently shows a neutral. The stock trades at a P/E of 43.0 with a market cap of ₹37,108 Cr. Investors should review the full earnings analysis for detailed insights.
Is Narayana Hrudaya planning capital expenditure?
FY26 capex guidance is around INR 400-450 crores excluding replacement costs; INR 425 crores projected spend (Page 15).
Keep Narayana Hrudaya on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
